Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Pradaxa Dabigatran etexilate Atrial fibrillation prevention of stroke and systemic embolism List with clinical criteria and/or conditions Complete
Praluent Alirocumab Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia Reimburse with clinical criteria and/or conditions Complete
Praxbind Idarucizumab (Drug Plan Submission) Reversal of dabigatran anticoagulant effects Withdrawn
Prevymis letermovir Cytomegalovirus infection (CMV), prophylaxis Suspended
Prevymis letermovir Cytomegalovirus infection, prophylaxis Reimburse with clinical criteria and/or conditions Complete
Prexige Lumiracoxib Osteoarthritis (Knee) Do not list Complete
Prezcobix Darunavir/cobicistat HIV Infection List with criteria/condition Complete
Prezista Darunavir HIV infection List with clinical criteria and/or conditions Complete
Prezista Darunavir HIV (treatment naive) List with clinical criteria and/or conditions Complete
Prezista Darunavir HIV infection (Pediatric) List with clinical criteria and/or conditions Complete